Ultragenyx Pharmaceutical Inc. unveiled positive 14-month data on 11 June from the Phase II portion of a potentially registrational trial of setrusumab in osteogenesis imperfecta (OI), which multiple analysts said will de-risk the drug’s chances of succeeding in the trial’s Phase III portion. Interim Phase III readouts for the drug, partnered with UK-based Mereo BioPharma Group plc, are expected in late 2024 or early-to-mid 2025.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?